Citius Pharmaceuticals, Inc. financial data

Symbol
CTXR on Nasdaq
Location
11 Commerce Drive, 1 St Floor, Cranford, NJ
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 41.4 % -92.7%
Quick Ratio 30.3 %
Debt-to-equity 81.3 % +505%
Return On Equity -23.1 % +44%
Return On Assets -20.4 % +26.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17M shares -90.6%
Common Stock, Shares, Outstanding 14.5M shares -92%
Entity Public Float 157M USD -34.6%
Common Stock, Value, Issued 14.5K USD -92%
Weighted Average Number of Shares Outstanding, Basic 11M shares +58.3%
Weighted Average Number of Shares Outstanding, Diluted 11M shares +58.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 40.9M USD +245%
General and Administrative Expense 20.1M USD +18.9%
Operating Income (Loss) -41.1M USD -0.17%
Nonoperating Income (Expense) 1.71K USD -99.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -41.1M USD -9.07%
Income Tax Expense (Benefit) 144K USD 0%
Net Income (Loss) Attributable to Parent -11.5M USD -34.7%
Earnings Per Share, Basic -4 USD/shares +49.1%
Earnings Per Share, Diluted -4 USD/shares +49.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.09M USD -66%
Inventory, Net 17.2M USD
Assets, Current 24.6M USD -12.1%
Property, Plant and Equipment, Net 275 USD -89.6%
Operating Lease, Right-of-Use Asset 881K USD +194%
Goodwill 9.35M USD 0%
Other Assets, Noncurrent 102M USD
Assets 128M USD +31.5%
Accounts Payable, Current 10.1M USD +507%
Employee-related Liabilities, Current 3.71M USD +118%
Accrued Liabilities, Current 8.52M USD +1448%
Liabilities, Current 51.8M USD +1149%
Deferred Income Tax Liabilities, Net 7.51M USD +14.3%
Operating Lease, Liability, Noncurrent 767K USD +808%
Liabilities 60.1M USD +456%
Retained Earnings (Accumulated Deficit) -231M USD -21.1%
Stockholders' Equity Attributable to Parent 65.1M USD -24.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 67.6M USD -21.7%
Liabilities and Equity 128M USD +31.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.73M USD +23%
Net Cash Provided by (Used in) Financing Activities 2.57M USD
Common Stock, Shares Authorized 250M shares -37.5%
Common Stock, Shares, Issued 14.5M shares -92%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.09M USD -66%
Deferred Tax Assets, Valuation Allowance 53.8M USD +19.8%
Operating Lease, Liability 882K USD +176%
Depreciation 578 USD -20.8%
Lessee, Operating Lease, Liability, to be Paid 1.07M USD +217%
Operating Lease, Liability, Current 115K USD -51.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 233K USD +985%
Lessee, Operating Lease, Liability, to be Paid, Year One 193K USD -24.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) 264K USD +83.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 191K USD +935%
Lessee, Operating Lease, Liability, to be Paid, Year Three 238K USD
Deferred Tax Assets, Operating Loss Carryforwards 39.9M USD +14%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 243K USD
Additional Paid in Capital 296M USD +7.17%
Share-based Payment Arrangement, Expense 12.8M USD +161%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%